COMPANY:

Inocras

"Today, Inocras...announced MRDVision, its solution for minimal residual disease (MRD) detection, validated to CLIA standards. The assay, previously available for research use only, is now ready for use in clinical settings, redefining the standard in MRD testing by enabling ultra-sensitive detection of circulating tumor DNA (ctDNA) with a simulated limit of detection (LOD) as low as 1 part per million (ppm)...Developed through the integration of Inocras’s comprehensive CancerVision™ WGS cancer profiling platform and Ultima Genomics’ ppmSeq™ technology, MRDVision delivers a breakthrough approach for tracking cancer recurrence and treatment response with unmatched accuracy, efficiency, and cost-effectiveness."

"Today, Inocras announced the signing of a groundbreaking Collaborative Research Agreement with the Center for Data Driven Discovery in Biomedicine (D3b) to advance research into rare sinonasal cancers. Under the agreement, Inocras will conduct Whole Genome Sequencing (WGS) and bioinformatic analysis on rare sinonasal cancer samples provided by D3b."

"Inocras Inc...and Summit Pharmaceuticals International Corporation...signed an MOU (Memorandum of understanding) to jointly explore the commercialization of their whole genome sequencing (WGS) analysis services. This collaboration aims to revolutionize healthcare in Japan by leveraging genomic data and bioinformatics to better understand and treat cancer and other genetic conditions. WGS reads an individual’s entire genome, generating vast data. Inocras' bioinformatics platform transforms this data into actionable clinical insights, enabling precise diagnoses support and personalized treatments. Inocras...has partnered with SPI to bring cutting-edge genomic solutions to the Japanese market. In particular, their proprietary technology (*) and bioinformatics pipeline are expected to provide valuable insights in genomic medicine."

"Inocras...has introduced MRDVision, a minimal residual disease (MRD) detection solution showcasing a limit of detection (LOD) down to one-in-a-million. MRDVision combines Inocras’s WGS cancer profiling platform, CancerVision, and Ultima Genomics’ ppmSeq™ technology to deliver high-accuracy detection of circulating tumor DNA. This assay offers a low limit of detection, straightforward workflow, and fast turnaround time, all at a low cost."

"Inocras...released a new study highlighting the clinical validation of its CancerVision Target-Enhanced Whole-Genome Sequencing (TE-WGS). In a head-to-head comparison with Ilumina’s widely-used TSO500, Inocras demonstrated TE-WGS’s ability to match the industry standard for biomarker detection in oncology, while also offering additional insights that enhance clinical understanding."

"Inocras...has entered an agreement with researchers at the Broad Institute of MIT and Harvard for a joint analysis of whole-genome sequencing data from cancer...Leveraging their combined expertise, Inocras along with the Broad team will analyze a substantial dataset of cancer profiles to uncover novel insights in cancer genomics. Inocras will serve as the major research collaborator and sponsor of this endeavor."

"Inocras Inc., a leader in whole genome sequencing and bioinformatics, announced today that it is now offering whole genome sequencing services using the UG 100TM sequencer from Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput, low cost, next-generation sequencing (NGS) architecture."

"Inocras...and Watchmaker Genomics...are thrilled to announce an expansion of their partnership to deliver solutions aimed at accelerating insights for patients and researchers...During development, Inocras rigorously tested several library preparation chemistries and ultimately selected the Watchmaker DNA Library Prep Kits with Fragmentation for its high library conversion efficiency, low-bias sequence coverage, and excellent sequence accuracy with challenging formalin-fixed, paraffin-embedded (FFPE) tissues."

"Inocras...and Massive Bio...have joined forces to set a new standard for cancer patient care. This strategic collaboration leverages Inocras's expertise in whole genome sequencing (WGS) and bioinformatics alongside Massive Bio's advanced AI technology for clinical trial matching, with the shared mission of enhancing personalized care for cancer patients."

"Inocras Inc...is proud to present groundbreaking research on radiogenomics and homologous recombination deficiency (HRD) in breast cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting...The study utilized a WGS-HRD approach to identify and validate radiomic features with predictive value for HRD, highlighting their potential as non-invasive imaging biomarkers for primary HRD screening."

"Inocras and IMBdx have announced a partnership aimed at enhancing care for cancer patients in the U.S. Through this partnership, Inocras, a leader in whole genome sequencing diagnostics, and IMBdx, an innovator in liquid biopsy-based diagnostics for cancer, will be able to provide broader offerings for cancer patients and their providers....The partnership will focus on Inocras providing IMBdx’s liquid biopsy-based cancer diagnostics in the U.S. market, creating alternatives for patients and their providers when genetic testing from tissue biopsy is not feasible. This joint initiative introduces a new model of patient care, leveraging advanced two technologies in genetic testing - whole genome data and liquid biopsy."

"Getlabs...has joined forces with Inocras...that empowers patients with critical genetic insights for cancer and rare diseases...Inocras provides whole genome sequencing tests, which deliver patients deep insights into their cancer and rare disease by providing comprehensive and detailed analyses of an individual's genetic composition."